Roberto Pili MD
Roberto Pili
MD
Associate Dean for Cancer Research and Integrative Oncology
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Medical Oncology; Oncology
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDProfessional Summary:
My laboratory has been engaged in translational research in the field of genitourinary malignancies for the past 20 years. After my clinical research training and establishing a kidney cancer research program at Johns Hopkins, I took the leadership of the Genitourinary Program at Roswell Park and then led the Experimental and Developmental Therapeutic Program at the Simon Comprehensive Cancer Center at Indiana University.
I moved recently to the University at Buffalo to build a new cancer research program. Our laboratory and clinical research interests have focused on drug development for genitourinary malignancies. In particular, we have been studying the therapeutic role of histone deacetylase inhibitors in modulating tumor differentiation, angiogenesis and immune responses. We have developed and tested several rational combination strategies of HDAC inhibitors with VEGF and mTOR inhibitors in preclinical models and translated them into clinical trials for bladder, renal cell and prostate carcinoma patients. Moreover, we have shown the synergy between HDAC inhibition and immune therapies and we are conducting clinical trials to test this hypothesis. More recently, we have been testing the role of dietary protein restriction in modulating the immune response.
Education and Training:
- Fellowship, Medical Oncology, Johns Hopkins University (2000)
- Fellowship, Biological Chemistry, National Institutes of Health, National Institute on Aging (1994)
- MD, Catholic University School of Medicine, Summa Cum Laude (1989)
Employment:
- Associate Dean for Cancer Research and Integrative Oncology, Medicine, Jacobs School of Medicine & Biomedical Sciences Jacobs School of Medicine (2020-present)
- Chief, Division of Hematology/Oncology, UBMD-Internal Medicine (2020-present)
- Director, Center for Nutritional Sciences and Cancer Therapeutics, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo (2020-present)
- Professor of Medicine, Medicine, Jacobs School of Medicine & Biomedical Sciences Jacobs School of Medicine & Biomedical Sciences (2020-present)
- Vice President, Oncology Services, Great Lake Cancer Care (2020-present)
- Adjunct Professor of Biological Sciences, Purdue University, Center for Cancer Research (2015–2020)
- Adjunct Professor of Pharmacology and Toxicology, Indiana University, School of Medicine (2015–2020)
- Co-Leader, Experimental and Developmental Therapeutics Program, Indiana University-Simon Cancer Center (2015–2020)
- Co-Leader, Indiana Genitourinary Cancers Research Consortium, Indiana University-Simon Cancer Center (2015–2020)
- Director, Genitourinary Oncology Division of Hematology Oncology, Indiana University, School of Medicine (2015–2020)
- Professor of Medicine and Urology, Indiana University-Simon Cancer Center (2015–2020)
- Robert Wallace Miller Professor of Oncology, Indiana University-Simon Cancer Center (2015–2020)
- Adjunct Associate Professor of Oncology and Urology, The Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2009–2020)
- Professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo (2013–2015)
- Chief, Genitourinary Section, Roswell Park Cancer Institute (2009–2015)
- Leader, Genitourinary Program, Roswell Park Cancer Institute (2009–2015)
- Professor of Oncology, Roswell Park Cancer Institute (2009–2015)
- Research Professor, Member, Department of Cancer Pathology and Prevention, Roswell Park Division (2009–2015)
- Associate Professor of Oncology and Urology, The Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2001–2008)
- Instructor in Oncology, The Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2000–2001)
UB 2020 Strategic Strengths:
- Health and Wellness Across the Lifespan
Grants and Sponsored Research:
- –August 2023
Therapeutic targeting of TFE3 in translocation renal cell carcinoma
DoD
Role: Principal Investigator
$221 - Epigenetic mechanisms of drug resistance in renal cell carcinoma
NCI
Role: Principal Investigator
$430
Patents:
- Therapeutic Targeting of Receptor Tyrosine Kinase Inhibitor- Induced Androgen Receptor Phosphoryaltion In Prostate Cancer (2018)
- Therapeutic Targeting of Sunitinib-Induced Androgen Receptor Phosphorylation in Renal Cell Carcinoma (2018)
Journal Articles:
- Satheeshkumar PS, Pili R, Epstein JB, Thazhe SBK, Sukumar R, Mohan MP. (2023) Characteristics and predictors associated with cancer-related fatigue among solid and liquid tumors. Journal of cancer research and clinical oncology (Aug).
- Rupert C, Dell' Aversana C, Mosca L, Montanaro V, Arcaniolo D, De Sio M, Bilancio A, Altucci L, Palinski W, Pili R, de Nigris F. (2023) Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models. Journal of experimental & clinical cancer research : CR (May), 42(1): 134. doi:10.1186/s13046-023-02713-1
- Hadisurya M, Lee ZC, Luo Z, Zhang G, Ding Y, Zhang H, Iliuk AB, Pili R, Boris RS, Tao WA. (2023) Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation. Molecular & cellular proteomics : MCP (May), 22(5): 100536. doi:10.1016/j.mcpro.2023.100536
- Knudsen S, Hansen A, Foegh M, Petersen S, Mekonnen H, Jia L, Shah P, Martin V, Frykman G, Pili R. (2023) A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors. PloS one (Jan), 18(8): e0290681. doi:10.1371/journal.pone.0290681
- Secinti E, Wu W, Krueger EF, Hirsh AT, Torke AM, Hanna NH, Adra N, Durm GA, Einhorn L, Pili R, Jalal SI, Mosher CE. (2022) Relations of perceived injustice to psycho-spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making. Psycho-oncology (Dec), 31(12): 2177-2184. doi:10.1002/pon.6065
- Cordova RA, Misra J, Amin PH, Klunk AJ, Damayanti NP, Carlson KR, Elmendorf AJ, Kim HG, Mirek ET, Elzey BD, Miller MJ, Dong XC, Cheng L, Anthony TG, Pili R, Wek RC, Staschke KA. (2022) GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. eLife (Sep), 11. doi:10.7554/eLife.81083
- He X, Zhou S, Dolan M, Shi Y, Wang J, Quinn B, Jahagirdar D, Huang WC, Tsuji M, Pili R, Ito F, Ortega J, Abrams SI, Ebos JML, Lovell JF. (2021) Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model. Journal for immunotherapy of cancer (Dec), 9(12). doi:10.1136/jitc-2021-003101
- Caston RA, Shah F, Starcher CL, Wireman R, Babb O, Grimard M, McGeown J, Armstrong L, Tong Y, Pili R, Rupert J, Zimmers TA, Elmi AN, Pollok KE, Motea EA, Kelley MR, Fishel ML. (2021) Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models. Journal of cellular and molecular medicine (Jan), 25(2): 784-800. doi:10.1111/jcmm.16132
- Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. (2020) Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British journal of cancer (Nov), 123(11): 1590-1598. doi:10.1038/s41416-020-01041-x
- Beketova E, Fang S, Owens JL, Liu S, Chen X, Zhang Q, Asberry AM, Deng X, Malola J, Huang J, Li C, Pili R, Elzey BD, Ratliff TL, Wan J, Hu CD. (2020) Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. Cancer research (Nov), 80(22): 4904-4917. doi:10.1158/0008-5472.CAN-20-1228
- Kays JK, Koniaris LG, Cooper CA, Pili R, Jiang G, Liu Y, Zimmers TA. (2020) The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers (Basel) (Jun), 12(6).
- Trott JF, Aboud OA, McLaughlin B, Anderson KL, Modiano JF, Kim K, Jen KY, Senapedis W, Chang H, Landesman Y, Baloglu E, Pili R, Weiss RH. (2020) Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer. Kidney360 (May), 1(5): 376-388. doi:10.34067/KID.0000282019
- Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. (2020) Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Mol Cancer Ther (Jan), 19(1): 147-156.
- Affronti HC, Rowsam AM, Pellerite AJ, Rosario SR, Long MD, Jacobi JJ, Bianchi-Smiraglia A, Boerlin CS, Gillard BM, Karasik E, Foster BA, Moser M, Wilton JH, Attwood K, Nikiforov MA, Azabdaftari G, Pili R, Phillips JG, Casero RA, Smiraglia DJ. (2020) Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nat Commun (Jan), 11(1): 52-52.
- Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. (2020) CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO precision oncology (Jan), 4: 370-381. doi:10.1200/PO.19.00399
- Scognamiglio G, De Chiara A, Parafioriti A, Armiraglio E, Fazioli F, Gallo M, Aversa L, Camerlingo R, Cacciatore F, Colella G, Pili R, de Nigris F. (2019) Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br J Cancer (Nov), 121(11): 979-982.
- Fishel ML, Xia H, McGeown J, McIlwain DW, Elbanna M, Craft AA, Kaimakliotis HZ, Sandusky GE, Zhang C, Pili R, Kelley MR, Jerde TJ. (2019) Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Mol Cancer Ther (Nov), 18(11): 1947-1960.
- Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. (2019) Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs (Oct).
- Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. (2019) TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Jan), 18(17): 2055-2066.
- Gawroński AR, Lin YY, McConeghy B, LeBihan S, Asghari H, Koçkan C, Orabi B, Adra N, Pili R, Collins CC, Sahinalp SC, Hach F. (2019) Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA. Nucleic Acids Res (Jan), 47(7): 38-38.
- Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. (2019) A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist (Jan), 24(9): 1151-1817.
- Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia D, Abrams SI, Pili R. (2018) Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clin Cancer Res (Dec), 24(24): 6383-6395.
- Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res (Dec), 24(23): 5977-5989.
- Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. (2018) Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs (Oct), 36(5): 919-926.
- Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK. (2018) Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clin Cancer Res (Jan), 24(18): 4399-4406.
- Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ. (2018) Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol (Jan), 4(7): 944-951.
- Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA. (2018) Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clin Cancer Res (Jan), 24(2): 306-315.
- Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R. (2018) Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. Cancer Res (Jan), 78(11): 2886-2896.
- Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis (Jan), 21(3): 425-532.
- Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, Barrera G. (2018) Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med (Jan), 115: 447-457.
- Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, Wang J, Woloszynska-Read A. (2017) Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death Dis (Dec), 8(12): 3217-3217.
- Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. (2017) EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res (Dec), 77(23): 6651-6666.
- Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. (2017) Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clin Cancer Res (Dec), 23(23): 7199-7208.
- Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. (2017) A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clin Genitourin Cancer (Dec), 15(6): 642-651.
- Affronti HC, Long MD, Rosario SR, Gillard BM, Karasik E, Boerlin CS, Pellerite AJ, Foster BA, Attwood K, Pili R, Wilton JH, Campbell MJ, Smiraglia DJ. (2017) Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. Oncotarget (Nov), 8(61): 103758-103774.
- Sanfrancesco JM, Eble JN, Grignon DJ, Wang M, Zhang S, Sundaram CP, Idrees MT, Pili R, Kouba E, Cheng L. (2017) Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intra- and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Mol Carcinog (Nov), 56(11): 2527-2537.
- Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L. (2017) Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Curr Drug Metab (Oct), 18(8): 700-711.
- Damayanti NP, Buno K, Cui Y, Voytik-Harbin SL, Pili R, Freeman J, Irudayaraj JMK. (2017) Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells. ACS Sens (Aug), 2(8): 1225-1230.
- Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R. (2017) Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clin Genitourin Cancer (Jul).
- Marshall JR, Burk RF, Payne Ondracek R, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R. (2017) Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget (Apr), 8(16): 26312-26322.
- Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. (2017) Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. Br J Cancer (Mar), 116(7): 874-883.
- Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R. (2017) Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res (Jan), 23(17): 5187-5201.
- Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA. (2017) Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. Lab Chip (Jan), 17(3): 415-428.
- Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, Hu CD. (2017) Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene (Jan), 36(9): 1223-1231.
- Adra N, Cheng L, Pili R. (2017) Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Clin Genitourin Cancer (Jan), 15(3): 517-519.
- Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R. (2016) Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget (Nov), 7(47): 76374-76389.
- Chintala S, Pili R. (2016) Genomic profiling of collecting duct renal carcinoma. Aging (Albany NY) (Oct), 8(10): 2260-2261.
- Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM. (2016) A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. Br J Cancer (Oct), 115(8): 940-948.
- Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, Hanna N, Callaghan JT, Skaar TC, Helft PR, Shahda S, O'Neil BH, Schneider BP. (2016) Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget (Aug), 7(35): 56491-56500.
- Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R. (2016) Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget (May), 7(21): 29901-29915.
- Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England) (May), 387(10032): 2008-16. doi:10.1016/S0140-6736(16)00559-6
- Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. (2016) Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (Mar), 22(6): 1356-63.
- Shen L, Orillion A, Pili R. (2016) Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics (Mar), 8(3): 415-428.
- Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R. (2016) YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene (Mar), 35(12): 1541-1553.
- Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S. (2016) Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clin Genitourin Cancer (Feb), 14(1): 59-65.
- Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M. (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol (Jan), 34(22): 2636-2643.
- Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. (2016) HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. BMC Cancer (Jan), 16: 617-617.
- Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R. (2016) Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. Prostate (Jan), 76(13): 1192-1202.
- Lamming DW, Cummings NE, Rastelli AL, Gao F, Cava E, Bertozzi B, Spelta F, Pili R, Fontana L. (2015) Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget (Oct), 6(31): 31233-31240.
- Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M. (2015) Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget (Sep), 6(27): 24376-24392.
- Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P. (2015) Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (Jul), 18(3): 233-244.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. (2015) Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw (Jun), 13(6): 772-799.
- Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res (Feb), 3(2): 136-148.
- Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther (Feb), 14(2): 513-522.
- Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. (2015) Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget (Feb), 6(5): 3136-3146.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. (2015) Kidney cancer, version 3.2015. J Natl Compr Canc Netw (Feb), 13(2): 151-159.
- Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther (Jan), 14(1): 101-110.
- Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM. (2014) Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience (Dec), 1(12): 844-853.
- Pili R, Carducci M, Brown P, Hurwitz H. (2014) An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs (Dec), 32(6): 1258-1268.
- Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. (2014) Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLoS One (Nov), 9(11): 112371-112371.
- Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ. (2014) Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol (Nov), 32(8): 1308-1316.
- Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R. (2014) Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene (Oct), 33(41): 4961-4965.
- Ellis L, Lehet K, Ku S, Azabdaftari G, Pili R. (2014) Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience (Oct), 1(10): 609-613.
- Kato Y, Yoshino I, Egusa C, Maeda T, Pili R, Tsuboi R. (2014) Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. Journal of dermatological science (Aug), 75(2): 140-7.
- Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. (2014) Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. PLoS One (Jul), 9(7): 103680-103680.
- Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, Rao G, Mehedint D, George S, Attwood K, Kauffman E, Narashima D, Khushalani NI, Pili R, Schwaab T. (2014) High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology (May), 83(5): 1129-1134.
- Tracz A, Mastri M, Lee CR, Pili R, Ebos JM. (2014) Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. J Vis Exp (Apr)(86).
- Gupta N, Al Ustwani O, Shen L, Pili R. (2014) Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Onco Targets Ther (Feb), 7: 223-234.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. (2014) Kidney cancer, version 2.2014. J Natl Compr Canc Netw (Feb), 12(2): 175-182.
- Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. (2014) Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol (Jan), 73(1): 1-8.
- Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA. (2014) Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist (Jan), 19(1): 51-60.
- Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (Dec), 11(4): 477-483.
- Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R. (2013) Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget (Dec), 4(12): 2451-2461.
- Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. (2013) Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget (Dec), 4(12): 2225-2236.
- Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. (2013) Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (Dec), 19(24): 6891-6901.
- Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA. (2013) Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology (Dec), 82(6): 1370-1375.
- Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R, Buck M. (2013) Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene (Nov).
- Ramakrishnan S, Ellis L, Pili R. (2013) Histone modifications: implications in renal cell carcinoma. Epigenomics (Aug), 5(4): 453-462.
- Batty N, Yarlagadda N, Pili R. (2013) Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. J Natl Compr Canc Netw (Aug), 11(8): 911-915.
- Ramakrishnan S, Pili R. (2013) Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J (Jul), 19(4): 333-340.
- Chatterjee S, Alsaeedi N, Hou J, Bandaru VV, Wu L, Halushka MK, Pili R, Ndikuyeze G, Haughey NJ. (2013) Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One (May), 8(5): 63726-63726.
- George S, Pili R. (2013) Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep (Apr), 15(2): 65-68.
- Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, Robertson D, Soffe J, Erler JT, Pili R, Springer CJ, Mather SJ, Reynolds AR. (2012) Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis (Dec), 15(4): 623-641.
- Minelli R, Cavalli R, Ellis L, Pettazzoni P, Trotta F, Ciamporcero E, Barrera G, Fantozzi R, Dianzani C, Pili R. (2012) Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci (Nov), 47(4): 686-694.
- Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. (2012) A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol (Oct), 23(10): 2714-2719.
- Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. (2012) Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist (Sep), 17(12): 1508-1514.
- Shen L, Pili R. (2012) Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology (Sep), 1(6): 948-950.
- Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. (2012) Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (Aug), 70(2): 305-313.
- Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM. (2012) Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer (Jul), 12: 293-293.
- Ebos JM, Pili R. (2012) Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical cancer research : an official journal of the American Association for Cancer Research (Jul), 18(14): 3719-21.
- Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. (2012) Development of a castrate resistant transplant tumor model of prostate cancer. Prostate (May), 72(6): 587-591.
- Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (May), 48(7): 1031-1037.
- Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. (2012) A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs (Apr), 30(2): 794-802.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. (2012) Testicular cancer. J Natl Compr Canc Netw (Apr), 10(4): 502-535.
- Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. (2012) Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther (Feb), 11(2): 383-392.
- Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. (2012) Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One (Jan), 7(1): 30815-30815.
- Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (Jan), 48(2): 202-208.
- Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer (Jan), 106(1): 77-84.
- Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (Dec), 17(23): 7337-7346.
- Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. (2011) A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs (Dec), 29(6): 1465-1474.
- Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. (2011) Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PLoS One (Nov), 6(11): 27178-27178.
- Pettazzoni P, Ciamporcero E, Medana C, Pizzimenti S, Dal Bello F, Minero VG, Toaldo C, Minelli R, Uchida K, Dianzani MU, Pili R, Barrera G. (2011) Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radic Biol Med (Oct), 51(8): 1610-1618.
- Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (Oct), 29(30): 4022-4028.
- George S, Pili R, Carducci MA, Kim JJ. (2011) Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw (Sep), 9(9): 1011-1018.
- O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W, Pili R, Schwaab T. (2011) Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?. Urology (Sep), 78(3): 595-600.
- Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. (2011) Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (Sep), 47(13): 1955-1961.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB, . (2011) Kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN (Sep), 9(9): 960-77.
- Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. (2011) A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol (Feb), 67(2): 431-438.
- Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. (2011) NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw (Feb), 9 Sup: 1-29.
- Tamaskar I, Dhillon J, Pili R. (2011) Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical advances in hematology & oncology : H&O (Feb), 9(2): 101-10.
- Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, Ciamporcero E, Dianzani MU, Barrera G, Pili R. (2011) Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med (Jan), 50(2): 313-322.
- Pili R. (2010) Is this a true renaissance for the treatment of prostate cancer?. Oncology (Williston Park) (Dec), 24(14): 1327-1328.
- Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. (2010) Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (Nov), 16(21): 5269-5276.
- Snyder CF, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. (2010) Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res (Aug), 19(6): 837-845.
- Ellis L, Pili R. (2010) Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (Aug), 3(8): 2411-2469.
- Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther (Jun), 9(6): 1525-1535.
- Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res (May), 16(10): 2906-2914.
- Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. (2010) The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology (Mar), 75(3): 608-14.
- Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. (2010) Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer (Feb), 10: 29-29.
- Salumbides BC, Lehet KM, Ndikuyeze G, Pili R. (2009) Pre-clinical models of renal carcinoma and their utility in drug development. Current protocols in pharmacology (Dec), Chapter 14: Unit 14.13.
- Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer (Dec), 115(23): 5541-9. doi:10.1002/cncr.24597
- Tamaskar I, Pili R. (2009) Update on novel agents in renal cell carcinoma. Expert review of anticancer therapy (Dec), 9(12): 1817-27.
- Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. (2009) Concordance of cancer patients. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (Oct), 18(8): 991-8.
- Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C. (2009) Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer (Sep), 115(18): 4110-7.
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Aug), 27(22): 3584-90. doi:10.1200/JCO.2008.20.1293
- Ellis L, Hammers H, Pili R. (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer letters (Aug), 280(2): 145-53. doi:10.1016/j.canlet.2008.11.012
- Kolmakova A, Rajesh M, Zang D, Pili R, Chatterjee S. (2009) VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconjugate journal (Jul), 26(5): 547-58.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. (2009) NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (Jun), 7(6): 618-630.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. (2009) NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (Jun), 7(6): 672-693.
- Pili R. (2009) Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clinical advances in hematology & oncology : H&O (Apr), 7(4): 252-4.
- Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America (Dec), 105(50): 19579-86. doi:10.1073/pnas.0809763105
- Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (Dec), 14(23): 7940-6. doi:10.1158/1078-0432.CCR-08-0221
- Lodge MA, Jacene HA, Pili R, Wahl RL. (2008) Reproducibility of tumor blood flow quantification with 15O-water PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (Oct), 49(10): 1620-7. doi:10.2967/jnumed.108.052076
- L. (2008) Feasibility and potential cost/benefit of routine isoflurane sedation using an anesthetic-conserving device: a prospective observational study. Respiratory care (Oct), 53(10): 1295-303.
- Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. (2008) Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Jun), 26(18): 2959-65. doi:10.1200/JCO.2007.15.1928
- Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research (Jun), 14(11): 3589-97.
- Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. (2008) Symptoms, supportive care needs, and function in cancer patients: how are they related?. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (Jun), 17(5): 665-77. doi:10.1007/s11136-008-9331-8
- Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA. (2008) Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Apr), 26(12): 1940-7. doi:10.1200/JCO.2007.14.5730
- Li J, Jameson MB, Baguley BC, Pili R, Baker SD. (2008) Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (Apr), 14(7): 2102-10.
- Nguyen QD, Shah SM, Hafiz G, Do DV, Haller JA, Pili R, Zimmer-Galler IE, Janjua K, Symons RC, Campochiaro PA. (2008) Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. American journal of ophthalmology (Feb), 145(2): 257-266. doi:10.1016/j.ajo.2007.09.025
- Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. (2007) The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PloS one (Sep), 2(9): e844. doi:10.1371/journal.pone.0000844
- Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. (2007) Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer biology & therapy (Sep), 6(9): 1360-7. doi:10.4161/cbt.6.9.4541
- Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. (2007) Platelets take up the monoclonal antibody bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research (Sep), 13(18 Pt 1): 5341-7.
- Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R. (2007) Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (Aug), 13(15 Pt 1): 4538-46.
- Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. (2007) Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. The Prostate (Aug), 67(11): 1182-93.
- Verheul HM, Qian DZ, Carducci MA, Pili R. (2007) Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer chemotherapy and pharmacology (Aug), 60(3): 329-39.
- Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. (2007) Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical cancer research : an official journal of the American Association for Cancer Research (Jul), 13(14): 4201-8.
- Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. (2007) Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology (Mar), 69(3): 526-31.
- Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R, Baker SD. (2007) A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. Journal of pharmaceutical and biomedical analysis (Jan), 43(2): 784-7. doi:10.1016/j.jpba.2006.08.006
- Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular cancer therapeutics (Jan), 6(1): 70-81.
- Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. (2006) Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate (Dec), 66(16): 1768-78.
- Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Sep), 24(25): 4092-9.
- Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer research (Sep), 66(17): 8814-21.
- Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. (2006) Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology (Aug), 29(4): 395-8.
- Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Liu JO. (2006) Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of medicinal chemistry (May), 49(9): 2677-80.
- Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical cancer research : an official journal of the American Association for Cancer Research (Jan), 12(2): 634-42.
- Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. (2005) A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical prostate cancer (Sep), 4(2): 138-41.
- Link RE, Allaf ME, Pili R, Kavoussi LR. (2005) Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Aug), 23(24): 5762-73.
- Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. (2005) Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clinical cancer research : an official journal of the American Association for Cancer Research (Jun), 11(12): 4437-43.
- Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. (2005) In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. The Prostate (Jun), 64(1): 20-8.
- Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R. (2005) Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (May), 11(9): 3535-42.
- Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA. (2005) Kidney cancer. Clinical practice guidelines. J Natl Compr Canc Netw (Jan), 3(1): 84-93.
- Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer research (Sep), 64(18): 6626-34.
- Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research (Jun), 10(11): 3577-85.
- Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. (2004) A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research (Jan), 24(1): 37-41.
- Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. (2003) CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer research (Sep), 63(18): 5978-91.
- Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. (2002) Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer cell (Dec), 2(6): 473-83.
- Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolò G, Sacchi N. (2002) Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer research (May), 62(9): 2455-61.
- Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer research (Feb), 61(4): 1477-85.
- Khan SR, Mhaka A, Pili R, Isaacs JT. (2001) Modified synthesis and antiangiogenic activity of linomide. Bioorganic & medicinal chemistry letters (Feb), 11(4): 451-2.
- Pili R, Chang J, Muhlhauser J, Crystal RG, Capogrossi MC, Passaniti A. (1997) Adenovirus-mediated gene transfer of fibroblast growth factor-1: angiogenesis and tumorigenicity in nude mice. International journal of cancer (Oct), 73(2): 258-63.
- Mühlhauser J, Merrill MJ, Pili R, Maeda H, Bacic M, Bewig B, Passaniti A, Edwards NA, Crystal RG, Capogrossi MC. (1995) VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circulation research (Dec), 77(6): 1077-86.
- Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. (1995) Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. International journal of cancer (Nov), 63(5): 673-9.
- Mühlhauser J, Pili R, Merrill MJ, Maeda H, Passaniti A, Crystal RG, Capogrossi MC. (1995) In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Human gene therapy (Nov), 6(11): 1457-65.
- Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, Passaniti A. (1995) The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer research (Jul), 55(13): 2920-6.
- Ziegelstein RC, Corda S, Pili R, Passaniti A, Lefer D, Zweier JL, Fraticelli A, Capogrossi MC. (1994) Initial contact and subsequent adhesion of human neutrophils or monocytes to human aortic endothelial cells releases an endothelial intracellular calcium store. Circulation (Oct), 90(4): 1899-907.
- Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. (1994) Altered angiogenesis underlying age-dependent changes in tumor growth. Journal of the National Cancer Institute (Sep), 86(17): 1303-14.
- Ziegelstein RC, Spurgeon HA, Pili R, Passaniti A, Cheng L, Corda S, Lakatta EG, Capogrossi MC. (1994) A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells. Circulation research (Jan), 74(1): 151-6.
- Guo Y, Pili R, Passaniti A. (1994) Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. The Prostate (Jan), 24(1): 1-10.
- Pili R, Corda S, Passaniti A, Ziegelstein RC, Heldman AW, Capogrossi MC. (1993) Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion. The Journal of clinical investigation (Dec), 92(6): 3017-22. doi:10.1172/JCI116925
- Bartoloni C, Guidi L, Pili R, Lewis ZA, Tricerri A, Cursi F, Gentiloni N, Cortesi E, Gambassi G. (1993) Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients. Oncology (Jan), 50(1): 27-34.
- Bartoloni C, Guidi L, Tricerri A, Patriarca F, Pili R, Cursi F, Canetta M, Cappelli A, Vangeli M, Salvati F. (1992) Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours. Oncology (Jan), 49(6): 426-30.
- Guidi L, Bartoloni C, Pellicanò P, Cappelli A, Cursi F, Pili R, Tricerri A, Patriarca F, Gambassi G. (1991) [Evaluation of latent changes in blood coagulation by the determination of plasma thrombin-antithrombin complex in gastrointestinal neoplasms]. La Clinica terapeutica (Mar), 136(6): 367-73.
- Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN. (1900) A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate chemistry (Jan), 15(6): 1416-23.
- Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN. (1900) A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate chemistry (Jan), 16(1): 43-50.
- Shen L, Pili R. (1900) Posttranscription regulation of prostate cancer growth. Cancer journal (Sudbury, Mass.) (Jan), 14(1): 46-53.
- Goldsamt A, Damayanti NP, De Nigris F, Pili R. (1900) Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions. Cancer journal (Sudbury, Mass.) (Jan), 26(5): 399-406.
- Shen L, Pili R. (1900) Tasquinimod targets suppressive myeloid cells in the tumor microenvironment. Oncoimmunology (Jan), 8(10): e1072672. doi:10.1080/2162402X.2015.1072672
Professional Memberships:
- American Society of Clinical Oncology
- American Association for Cancer Research
Presentations:
- "Nutrition and Kidney Cancer" JNKCF meeting (2023)
- "“Therapeutic targeting of TFE3 in translocation RCC”." NCI-Cincinnati Children Hospital, TFE RCC Conference, Covington KY (2023)
- "Nutrition and Kidney cancer" JNKCF meeting (2023)
- "“Latest Advances in Anticancer Drugs in Clinical Development”" 6th European Spring Oncology Conference (ESOC6) (2010)
- "“Therapeutic strategies to overcome antiVEGF resistance”" International Conference on Angiogenesis (2009)
- "“Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in pre-treated patients with renal cell carcinoma: Phase II results on safety and efficacy”" 8th International Symposium in Kidney Cancer (2009)
- "“Other antiangiogenesis approaches and issues in sequencing”" 5th European Spring Oncology Conference (ESOC 5) (2008)
- "“Medical management of Kidney cancer”" World conference on interventional radiology (2007)
- "“Histone Deacetylase Inhibitors”" 3rd International Kidney & Bladder Cancer Congress (2006)
- "Targeting Histone Deacetylase Inhibitors" 6th International Prostate Cancer Congress (2006)
- "Histone Deacetylase Inhibitors" 5th International prostate Cancer congress (2005)
Service Activities:
- Grant reviewer for Dod and NIH; Ad hoc reviewer for NIH study sections and Chair for DOD study section
- CoC/Buffalo General Medical Center & Millard Fillmore Suburban Hospital- Great Lakes Cancer Care Collaboratives; Cancer Liaison Physician-
- UB Cancer Research Consortium; Director
- UB Cancer Research Consortium Seminar Series; Director
- NCI- Cancer Prevention-CTNet Committee on Equity Diversity and Inclusions in clinical trials -; Member
- JCI, Cancer Research, JCO; reviewer
- Buffalo General Hospital site, UB/RPCCC Fellowship Program in Hematology Oncology; Site Director